A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial

ImmunotherapyFurther Publications Dermatology

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Lancet

Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Peña AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M, CheckMate 9DW investigators

doi: 10.1016/S0140-6736(25)00403-9

Further Publications Immunology

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Lancet

Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP

doi: 10.1016/S0140-6736(24)01774-4

Further Publications Immunology

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Lancet Infect Dis

Harris V, Holmes J, Gbinigie-Thompson O, Rahman NM, Richards DB, Hayward G, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Ahmed H, Carson-Stevens A, Nguyen-Van-Tam JS, Patel MG, Saville BR, Francis N, Thomas NPB, Evans P, Dobson M, Png ME, Lown M, van Hecke O, Jani BD, Hart ND, Butler D, Cureton L, Patil M, Andersson M, Coates M, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Yu LM, Hobbs FDR, Little P, Butler CC, PANORAMIC Trial Collaborative Group

doi: 10.1016/S1473-3099(24)00431-6

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Psoriasis

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial

Br J Dermatol

Zhang J, Ding Y, Wang P, Li L, Pan W, Lu Y, Cheng H, Jiang X, Ho JC, Guo S, Liu L, Chatterjee A, Kisa RM, Banerjee S

doi: 10.1093/bjd/ljae406

Immune Response

Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial

Crit Care

Arns B, Kalil AC, Sorio GGL, Boschi E, Antonio ACP, Antonio JP, Birriel DC, Lanziotti DH, da Cunha Abbott F, Rocha GC, de Fátima Fernandes V, de Souza Dantas VC, da Silva Medeiros GF, de França Diniz Rocha V, Pereira FC, Gobatto ALN, Lima VP, Lacerda FH, de Maio Carrilho CMD, de Oliveira Cardozo KDN, Irineu VM, Kurtz P, Horvath JDC, Sesin GP, Agani CAJO, Dos Santos TM, Brochier LSB, da Rosa BS, Tomazini BM, Besen BAMP, Pereira AJ, Veiga VC, Nascimento GM, Zavascki AP, OPTIMISE Study Group

doi: 10.1186/s13054-024-05178-6

Further Publications Dermatology

Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial

Lancet

Palmbergen WAC, Beekman R, Heeren AM, van Nuenen BFL, Alleman TWH, Verstraete E, Jellema K, Verhagen WIM, Visser LH, de Ruiter GCW, van de Beek D, de Borgie CAJM, Bogaards JA, de Bie RMA, Verhamme C, Dutch CTS study group

doi: 10.1016/S0140-6736(25)00368-X

Osteoporosis

A person-centred consultation intervention to improve shared decision-making about, and uptake of, osteoporosis medicines (iFraP): a pragmatic, parallel-group, individual randomised controlled trial protocol

NIHR Open Res

Bullock L, Nicholls E, Cherrington A, Butler-Walley S, Clark EM, Fleming J, Leyland S, Bentley I, Thomas S, Iglesias-Urrutia CP, Webb D, Smith J, Bathers S, Lewis S, Clifford A, Siciliano M, Protheroe J, Ryan S, Lefroy J, Dale N, Hawarden A, Connacher S, Horne R, O'Neill TW, Mallen CD, Jinks C, Paskins Z

doi: 10.3310/nihropenres.13571.1

Further Publications Immunology

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial

Lancet

Diallo F, Haidara FC, Tapia MD, Dominguez Islas CP, Alderson MR, Hausdorff WP, Martellet L, Hosken N, Kapse D, Kulkarni PS, Townsend-Payne K, Vanni F, Posavad CM, Sow SO, Kotloff KL, Chen WH, NmCV-5 EPI study team

doi: 10.1016/S0140-6736(25)00046-7

Related content

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial

Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial

Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial

A person-centred consultation intervention to improve shared decision-making about, and uptake of, osteoporosis medicines (iFraP): a pragmatic, parallel-group, individual randomised controlled trial protocol

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial